Drugs.com FDA Alerts · 1/13/2026
FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
Audience: Health Care Professional, Consumer January 13, 2026 FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications This information is an update to the FDA Drug Safety...
Why this is tracked
This item matched GLP-1, Medicare, Part D, CMS, FDA, coverage, pricing, prior authorization, or access terms used by the daily monitor.
Read the source
This page summarizes and links to the original source. Use the source article, CMS/FDA notices, plan documents, and clinician guidance for decisions.